Gubra Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Gubra's earnings have been declining at an average annual rate of -92.7%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 10% per year.
Belangrijke informatie
-92.7%
Groei van de winst
-124.4%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 26.8% |
| Inkomstengroei | 10.0% |
| Rendement op eigen vermogen | -10.0% |
| Nettomarge | -20.8% |
| Volgende winstupdate | 28 Feb 2025 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Gubra geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 224 | -47 | 86 | 97 |
| 31 Mar 24 | 214 | -46 | 80 | 93 |
| 31 Dec 23 | 205 | -45 | 75 | 89 |
| 30 Sep 23 | 204 | -26 | 73 | 83 |
| 30 Jun 23 | 204 | -7 | 71 | 77 |
| 31 Mar 23 | 201 | -1 | 69 | 67 |
| 31 Dec 22 | 199 | 4 | 67 | 57 |
| 31 Dec 21 | 255 | 68 | 52 | 27 |
| 31 Dec 20 | 172 | 13 | 45 | 34 |
Kwaliteitswinsten: PI3 is currently unprofitable.
Groeiende winstmarge: PI3 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: PI3 is unprofitable, and losses have increased over the past 5 years at a rate of 92.7% per year.
Versnelling van de groei: Unable to compare PI3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: PI3 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.7%).
Rendement op eigen vermogen
Hoge ROE: PI3 has a negative Return on Equity (-10.03%), as it is currently unprofitable.